CN103282046B - 芳基硫酸酯酶 a cns 递送的方法和组合物 - Google Patents

芳基硫酸酯酶 a cns 递送的方法和组合物 Download PDF

Info

Publication number
CN103282046B
CN103282046B CN201180040802.XA CN201180040802A CN103282046B CN 103282046 B CN103282046 B CN 103282046B CN 201180040802 A CN201180040802 A CN 201180040802A CN 103282046 B CN103282046 B CN 103282046B
Authority
CN
China
Prior art keywords
rhasa
brain
formulation
protein
stable formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201180040802.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN103282046A (zh
Inventor
N·萨拉马特-米勒
K·泰勒
P·坎波列托
Z·夏若克
J·潘
L·恰尔纳斯
T·L·莱特
P·加莱斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Shire Human Genetics Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Human Genetics Therapies Inc filed Critical Shire Human Genetics Therapies Inc
Priority to CN201510172262.0A priority Critical patent/CN104857504A/zh
Publication of CN103282046A publication Critical patent/CN103282046A/zh
Application granted granted Critical
Publication of CN103282046B publication Critical patent/CN103282046B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201180040802.XA 2010-06-25 2011-06-25 芳基硫酸酯酶 a cns 递送的方法和组合物 Active CN103282046B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510172262.0A CN104857504A (zh) 2010-06-25 2011-06-25 芳基硫酸酯酶a cns递送的方法和组合物

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US35885710P 2010-06-25 2010-06-25
US61/358,857 2010-06-25
US36078610P 2010-07-01 2010-07-01
US61/360,786 2010-07-01
US38786210P 2010-09-29 2010-09-29
US61/387,862 2010-09-29
US201161435710P 2011-01-24 2011-01-24
US61/435,710 2011-01-24
US201161442115P 2011-02-11 2011-02-11
US61/442,115 2011-02-11
US201161476210P 2011-04-15 2011-04-15
US61/476,210 2011-04-15
US201161495268P 2011-06-09 2011-06-09
US61/495,268 2011-06-09
PCT/US2011/041926 WO2011163650A2 (en) 2010-06-25 2011-06-25 Methods and compositions for cns delivery of arylsulfatase a

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201510172262.0A Division CN104857504A (zh) 2010-06-25 2011-06-25 芳基硫酸酯酶a cns递送的方法和组合物

Publications (2)

Publication Number Publication Date
CN103282046A CN103282046A (zh) 2013-09-04
CN103282046B true CN103282046B (zh) 2015-05-13

Family

ID=46888844

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180040802.XA Active CN103282046B (zh) 2010-06-25 2011-06-25 芳基硫酸酯酶 a cns 递送的方法和组合物

Country Status (26)

Country Link
US (1) US9770410B2 (enExample)
EP (3) EP3626257B1 (enExample)
JP (1) JP6045493B2 (enExample)
KR (5) KR102094094B1 (enExample)
CN (1) CN103282046B (enExample)
AU (5) AU2011270670B2 (enExample)
BR (1) BR112012033216B1 (enExample)
CA (1) CA2803003C (enExample)
CY (2) CY1122282T1 (enExample)
DK (1) DK2585104T3 (enExample)
ES (1) ES2754776T3 (enExample)
HR (1) HRP20191923T1 (enExample)
IL (3) IL291556B2 (enExample)
LT (1) LT2585104T (enExample)
ME (1) ME03647B (enExample)
MX (2) MX382443B (enExample)
NZ (2) NZ605873A (enExample)
PL (2) PL2585104T3 (enExample)
RS (1) RS59468B1 (enExample)
RU (1) RU2671503C2 (enExample)
SI (1) SI2585104T1 (enExample)
SM (1) SMT201900589T1 (enExample)
TW (1) TWI667037B (enExample)
UA (1) UA115650C2 (enExample)
WO (1) WO2011163650A2 (enExample)
ZA (1) ZA201300675B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3626258T (pt) 2010-06-25 2021-10-19 Shire Human Genetic Therapies Métodos e composições para fornecimento ao snc de iduronato-2-sulfatase
HRP20191924T1 (hr) 2010-06-25 2020-01-10 Shire Human Genetic Therapies, Inc. Postupci i sastavi za isporuku iduronat-2-sulfataze u cns
DK2588130T3 (en) 2010-06-25 2016-10-24 Shire Human Genetic Therapies Cns delivery of therapeutic agents
NZ605873A (en) 2010-06-25 2015-02-27 Shire Human Genetic Therapies Methods and compositions for cns delivery of arylsulfatase a
MX2013000320A (es) 2010-06-25 2013-06-05 Shire Human Genetic Therapies Composiciones y metodos para suministro al sistema nervioso central de heparan n-sulfatasa.
WO2013096899A2 (en) 2011-12-23 2013-06-27 Shire Human Genetic Therapies, Inc. Stable formulations for cns delivery of arylsulfatase a
CN119979504A (zh) 2013-01-09 2025-05-13 武田药品工业株式会社 含用于纯化芳基硫酸酯酶a的方法
RU2692251C2 (ru) * 2013-05-15 2019-06-24 Риджентс Оф Зэ Юниверсити Оф Миннесота Опосредованный аденоассоциированным вирусом перенос генов в центральную нервную систему
US10208734B2 (en) * 2015-04-23 2019-02-19 Continuum Dynamics, Inc. Lift-driven wind turbine with force canceling blade configuration
WO2017009255A1 (en) * 2015-07-10 2017-01-19 Synthon Biopharmaceuticals B.V. Compositions comprising antibody-duocarmycin drug conjugates
CN108883162A (zh) * 2016-02-17 2018-11-23 夏尔人类遗传性治疗公司 用于芳基硫酸酯酶a的cns递送的方法和组合物
NZ788906A (en) * 2016-06-01 2025-07-25 Servier Ip Uk Ltd Formulations of polyalkylene oxide-asparaginase and methods of making and using the same
KR102471458B1 (ko) 2016-12-28 2022-11-25 제이씨알 파마 가부시키가이샤 동결건조 제제
TWI835747B (zh) 2017-09-22 2024-03-21 賓州大學委員會 用於治療黏多醣病 ii 型之基因治療
KR20200107984A (ko) 2017-12-19 2020-09-16 샤이어 휴먼 지네틱 테라피즈 인크. 정제된 아릴설파타아제 a 및 이의 조성물
WO2020004368A1 (ja) * 2018-06-25 2020-01-02 Ｊｃｒファーマ株式会社 蛋白質含有水性液剤
WO2020227166A1 (en) * 2019-05-03 2020-11-12 The Trustees Of The University Of Pennsylvania Compositions useful in treatment of metachromatic leukodystrophy
WO2021061517A1 (en) * 2019-09-23 2021-04-01 University Of Washington Assay of arylsulfatase a enzymatic activity in dried blood spots by mass spectrometry and fluorometry
WO2024176112A1 (en) 2023-02-21 2024-08-29 Takeda Pharmaceutical Company Limited Large scale production of recombinant arylsulfatase a and compositions thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101410408A (zh) * 2006-04-04 2009-04-15 希尔制药爱尔兰有限责任公司 用于浓缩多肽的方法
CN101431960A (zh) * 2006-01-20 2009-05-13 建新公司 用于溶酶体贮积症的脑室内酶输注系统

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4743265A (en) 1986-04-23 1988-05-10 Dij Catheter Corp Articulated catheter placement device
US5863782A (en) 1995-04-19 1999-01-26 Women's And Children's Hospital Synthetic mammalian sulphamidase and genetic sequences encoding same
US6118045A (en) 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
ATE225184T1 (de) * 1997-08-22 2002-10-15 Seikagaku Kogyo Co Ltd Arzneimittel zur behandlung von durch hernie gestörter intervertebraler bandscheibe
WO2000034451A1 (en) 1998-12-07 2000-06-15 Pharming Intellectual Property B.V. Treatment of pompe's disease
US6217552B1 (en) 1999-03-01 2001-04-17 Coaxia, Inc. Medical device for selective intrathecal spinal cooling in aortic surgery and spinal trauma
US20020052311A1 (en) 1999-09-03 2002-05-02 Beka Solomon Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders
US6534300B1 (en) 1999-09-14 2003-03-18 Genzyme Glycobiology Research Institute, Inc. Methods for producing highly phosphorylated lysosomal hydrolases
US20020099025A1 (en) 1999-12-30 2002-07-25 Heywood James A. Treatment of neurological disorders
US6866844B2 (en) 2002-11-07 2005-03-15 Biomarin Pharmaceutical Inc. Precursor N-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US20040005309A1 (en) 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
ATE384736T1 (de) 2001-04-30 2008-02-15 Zystor Therapeutics Inc Subzelluläres targeting von therapeutischen proteinen
US20030072761A1 (en) 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
WO2003032913A2 (en) 2001-10-16 2003-04-24 Symbiontics Inc. Methods and compositions for targeting proteins across the blood brain barrier
JP5570677B2 (ja) 2002-04-25 2014-08-13 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド α−ガラクトシダーゼＡ欠損症の治療
EP1514106A4 (en) 2002-05-29 2007-05-09 Zystor Therapeutics Inc TARGETED THERAPEUTIC PROTEINS
US20040248262A1 (en) 2003-01-22 2004-12-09 Koeberl Dwight D. Constructs for expressing lysomal polypeptides
CA2525236C (en) 2003-06-20 2015-03-24 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US20050026823A1 (en) 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
NZ548871A (en) 2004-01-30 2009-06-26 Shire Pharmaceuticals Ireland Use of arylsulfatase A for treating metachromatic leukodystrophy
WO2005074888A2 (en) 2004-02-03 2005-08-18 Biodelivery Sciences International, Inc. Replacement enzyme cochleates
WO2005077093A2 (en) 2004-02-06 2005-08-25 Biomarin Pharmaceutical Inc. Manufacture of highly phosphorylated lysosomal enzymes and uses thereof
ES2344302T3 (es) 2004-02-10 2010-08-24 Zystor Therapeutics , Inc. Alfa glucosidasa acida y fragmentos de la misma.
US20050208090A1 (en) 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
JPWO2006121199A1 (ja) 2005-05-11 2008-12-18 日本ケミカルリサーチ株式会社 脂質小胞体組成物
CN104771402A (zh) 2005-06-08 2015-07-15 阿米库斯治疗学公司 溶酶体酶编码基因突变相关的cns紊乱的治疗
PL2631242T3 (pl) * 2006-04-04 2023-03-20 Takeda Pharmaceutical Company Limited Sposób zatężania polipeptydu
GB0611463D0 (en) 2006-06-09 2006-07-19 Novartis Ag Organic compounds
US20080140056A1 (en) 2006-12-06 2008-06-12 Medtronic, Inc. Method for delivering large molecules to the brain
US20090041741A1 (en) 2007-03-06 2009-02-12 Saint Louis University Modified enzyme and treatment method
BRPI0815416A2 (pt) * 2007-08-15 2014-10-21 Amunix Inc Composições e métodos para modificar propriedades de polipeptídeos biologicamente ativos
TWI661833B (zh) 2007-11-30 2019-06-11 百慕達商艾伯維生物技術有限責任公司 蛋白質調配物及製造其之方法
US7722865B2 (en) * 2008-01-18 2010-05-25 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
US20110223147A1 (en) 2008-05-07 2011-09-15 Zystor Therapeutics, Inc. Lysosomal targeting peptides and uses thereof
US8436489B2 (en) 2009-06-29 2013-05-07 Lightsail Energy, Inc. Compressed air energy storage system utilizing two-phase flow to facilitate heat exchange
MX2013000320A (es) 2010-06-25 2013-06-05 Shire Human Genetic Therapies Composiciones y metodos para suministro al sistema nervioso central de heparan n-sulfatasa.
HRP20191924T1 (hr) 2010-06-25 2020-01-10 Shire Human Genetic Therapies, Inc. Postupci i sastavi za isporuku iduronat-2-sulfataze u cns
DK2588130T3 (en) 2010-06-25 2016-10-24 Shire Human Genetic Therapies Cns delivery of therapeutic agents
NZ605873A (en) 2010-06-25 2015-02-27 Shire Human Genetic Therapies Methods and compositions for cns delivery of arylsulfatase a
PT3626258T (pt) 2010-06-25 2021-10-19 Shire Human Genetic Therapies Métodos e composições para fornecimento ao snc de iduronato-2-sulfatase
US20110318327A1 (en) 2010-06-25 2011-12-29 Shire Human Genetic Therapies, Inc. Treatment of sanfilippo syndrome type b
EP2588132A4 (en) 2010-06-25 2014-10-15 Shire Human Genetic Therapies METHOD AND COMPOSITIONS FOR DELIVERING BETA GALACTOCEREBROSIDASE INTO THE CNS
JP2012062312A (ja) 2010-08-19 2012-03-29 Yoshikatsu Eto ハンター症候群の治療剤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101431960A (zh) * 2006-01-20 2009-05-13 建新公司 用于溶酶体贮积症的脑室内酶输注系统
CN101410408A (zh) * 2006-04-04 2009-04-15 希尔制药爱尔兰有限责任公司 用于浓缩多肽的方法

Also Published As

Publication number Publication date
WO2011163650A2 (en) 2011-12-29
EP2585104A4 (en) 2014-01-15
EP3964230A1 (en) 2022-03-09
KR20230079472A (ko) 2023-06-07
TW201206464A (en) 2012-02-16
KR20130135821A (ko) 2013-12-11
KR102318997B1 (ko) 2021-10-29
IL291556B1 (en) 2023-10-01
KR102720061B1 (ko) 2024-10-22
US20120009171A1 (en) 2012-01-12
ME03647B (me) 2020-07-20
IL273854B (en) 2022-04-01
ES2754776T3 (es) 2020-04-20
HRP20191923T1 (hr) 2020-01-10
AU2021236557B2 (en) 2025-01-30
IL291556A (en) 2022-05-01
BR112012033216B1 (pt) 2022-10-11
SI2585104T1 (sl) 2019-11-29
KR102094094B1 (ko) 2020-03-27
TWI667037B (zh) 2019-08-01
WO2011163650A3 (en) 2013-06-13
AU2021236557A1 (en) 2021-10-28
EP3626257B1 (en) 2021-08-04
US9770410B2 (en) 2017-09-26
LT2585104T (lt) 2019-10-25
AU2019204051A1 (en) 2019-08-29
KR101997935B1 (ko) 2019-10-04
UA115650C2 (uk) 2017-12-11
IL223758B (en) 2020-04-30
NZ702799A (en) 2016-08-26
MX382443B (es) 2025-03-11
AU2019204051B2 (en) 2021-07-22
AU2011270670A1 (en) 2013-02-14
JP2013538788A (ja) 2013-10-17
SMT201900589T1 (it) 2020-03-13
BR112012033216A2 (pt) 2020-08-25
RU2671503C2 (ru) 2018-11-01
CA2803003C (en) 2022-11-22
PL3626257T3 (pl) 2022-03-28
CY1122282T1 (el) 2020-11-25
EP2585104A2 (en) 2013-05-01
IL291556B2 (en) 2024-02-01
PL2585104T3 (pl) 2020-01-31
CY1124910T1 (el) 2023-01-05
CN103282046A (zh) 2013-09-04
AU2011270670B2 (en) 2017-01-12
AU2025202376A1 (en) 2025-04-24
KR102537084B1 (ko) 2023-05-26
AU2017202289A1 (en) 2017-04-27
RU2012154574A (ru) 2014-07-27
AU2017202289B2 (en) 2019-03-14
MX344795B (es) 2017-01-05
CA2803003A1 (en) 2011-12-29
DK2585104T3 (da) 2019-10-14
JP6045493B2 (ja) 2016-12-14
MX2013000323A (es) 2013-06-05
NZ605873A (en) 2015-02-27
EP2585104B1 (en) 2019-08-21
KR20210131449A (ko) 2021-11-02
EP3626257A1 (en) 2020-03-25
KR20200035167A (ko) 2020-04-01
RS59468B1 (sr) 2019-11-29
KR20180059580A (ko) 2018-06-04
IL273854A (en) 2020-05-31
ZA201300675B (en) 2017-11-29

Similar Documents

Publication Publication Date Title
JP7543459B2 (ja) アリールスルファターゼａのｃｎｓ送達の方法および組成物
CN103282046B (zh) 芳基硫酸酯酶 a cns 递送的方法和组合物
CN103179980B (zh) 艾杜糖醛酸-2-硫酸酯酶的cns递送的方法和组合物
HK40069231A (en) Methods and compositions for cns delivery of arylsulfatase a
HK40022682A (en) Methods and compositions for cns delivery of arylsulfatase a
HK40022682B (en) Methods and compositions for cns delivery of arylsulfatase a
HK1184709B (en) Methods and compositions for cns delivery of arylsulfatase a
HK1184709A (en) Methods and compositions for cns delivery of arylsulfatase a

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20230329

Address after: Osaka, Japan

Patentee after: TAKEDA PHARMACEUTICAL Co.,Ltd.

Address before: Massachusetts

Patentee before: SHIRE HUMAN GENETIC THERAPIES, Inc.